Liver Disease Treatment Market

Global Liver Disease Treatment Market:

The global liver disease treatment market size reached US$ 23.8 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 39.4 Billion by 2032, exhibiting a growth rate (CAGR) of 5.7% during 2024-2032. The growing elderly population worldwide, which is prone to several chronic illnesses, including liver disease, is stimulating the market.

Liver Disease Treatment Market Analysis:

• Major Market Drivers: The fluctuating dietary habits and physical inactivity are propelling the market.
• Key Market Trends: The improving research and development activities, major growth in the healthcare industry, and the adoption of numerous government programs to promote public health are a few factors contributing to the liver disease treatment market growth.
• Competitive Landscape: Some of the major market companies include Abbott Laboratories, AbbVie Inc., Astellas Pharma Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Emergent BioSolutions Inc., F. Hoffmann-La Roche AG, Gilead Sciences Inc., GlaxoSmithKline plc, Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, and Viatris Inc., among many others.
• Geographical Trends: North America is currently dominating the market as a result of a rise in liver disorders, such as non-alcoholic fatty liver disease (NAFLD) and hepatitis, especially considering an upsurge in obesity and diabetes rates, which are major risk factors for liver conditions.
• Challenges and Opportunities: The high cost of advanced therapies, which limits patient access, is hampering the market. However, increasing government financing, enhancing insurance coverage, and encouraging research into more affordable treatment options will continue to catalyze the market over the forecast period.

Liver Disease Treatment Market Trends:

Increased Focus on Non-Alcoholic Fatty Liver Disease (NAFLD)

With the rise of obesity and diabetes, NAFLD has become a primary focus in liver disease treatment. Ongoing research focuses on looking into new pharmaceutical therapies to treat the disorder, as well as lifestyle changes that can reduce disease development. In July 2024, the Union Minister launched the Indo-French Liver and Metabolic Disease Network (InFLiMeN), a virtual node to prevent and cure non-alcoholic fatty liver disease (NAFLD) at the Institute of Liver and Biliary Sciences in New Delhi.

Growing Emphasis on Pharmaceutical Expansion

Pharmaceutical companies are rapidly investing in the discovery of new medications to treat liver illnesses. The increased incidence of chronic liver disorders, as well as the lucrative market potential for breakthrough medicines, are driving this trend, particularly in disease-prone countries. For instance, in February 2024, India's Zydus Lifesciences announced its aim to launch its first new drug in the United States by early 2026, looking to tap into the multi-billion-dollar market for treating a type of liver disease.

Rising Demand for Liver Transplants

As liver disease advances to end-stage liver failure in many people, the demand for liver transplants grows. Transplants are becoming more accessible owing to technological advancements such as minimally invasive methods and enhanced post-operative care. In May 2024, Wockhardt Hospitals, in collaboration with the South Asian Liver Institute, launched an early recovery program (ERP) for liver transplantation in Mumbai. The program aims to reduce the financial burden of liver transplants by approximately 20-30 %.

Global Liver Disease Treatment Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with the market forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on treatment type, disease type, and end user.

Breakup by Treatment Type:

• Antiviral Drugs
• Immunosuppressants
• Vaccines
• Immunoglobulins
• Corticosteroids
• Targeted Therapy
• Chemotherapy
   

Currently, antiviral drugs hold the largest liver disease treatment market share

The report has provided a detailed breakup and analysis of the market based on the treatment type. This includes antiviral drugs, immunosuppressants, vaccines, immunoglobulins, corticosteroids, targeted therapy, and chemotherapy. According to the report, antiviral drugs represented the largest market segmentation.

Antiviral drugs play an important role in this market since they target viral hepatitis, specifically hepatitis B and C. These medications lower viral load, protect the liver, and enhance patient outcomes, all of which contribute considerably to overall treatment efficacy.

Breakup by Disease Type:

• Hepatitis
• Autoimmune Diseases
• Non-alcoholic Fatty Liver Disease (NAFLD)
• Cancer
• Genetic Disorders
• Others
   

Among these, hepatitis holds the largest liver disease treatment market size

The report has provided a detailed breakup and analysis of the market based on the disease type. This includes hepatitis, autoimmune diseases, non-alcoholic fatty liver disease (NAFLD), cancer, genetic disorders, and others. According to the report, hepatitis represented the largest market segmentation.

Hepatitis, particularly types B and C, generates significant demand as antiviral medications, vaccinations, and liver care measures strive to reduce viral load, prevent liver damage, and manage consequences, making hepatitis a primary focus of treatment improvements.

Breakup by End User:

• Hospitals
• Ambulatory Surgical Centers
• Others
   

Currently, hospitals dominate the market with the largest liver disease treatment market share

The report has provided a detailed breakup and analysis of the market based on the end user. This includes hospitals, ambulatory surgical centers, and others. According to the report, hospitals represented the largest market segmentation.

The market caters to a wide range of end users, with hospitals serving as the key providers of advanced care. Hospitals provide specialist treatments such as surgeries, antiviral medications, and transplants, which are critical in treating and improving the outcomes of patients with liver disease.

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa
   

North America leads the market

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia-Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest liver disease treatment market share. 

North America exhibits a clear dominance in the market, driven by the increasing demand for liver transplants due to late-stage liver disease. This involves increased donor registration efforts and developments in transplantation technology. Furthermore, governments in this region actively finance projects that raise awareness and treat liver disease.

Competitive Landscape:

The report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major market companies have also been provided. Some of the key players in the market include:

• Abbott Laboratories
• AbbVie Inc.
• Astellas Pharma Inc.
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• Emergent BioSolutions Inc.
• F. Hoffmann-La Roche AG
• Gilead Sciences Inc.
• GlaxoSmithKline plc
• Merck & Co. Inc.
• Novartis AG
• Pfizer Inc.
• Sanofi S.A.
• Takeda Pharmaceutical Company Limited
• Viatris Inc.
   

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

Liver Disease Treatment Market Recent Developments:

• July 2024: The Union Minister launched the Indo-French Liver and Metabolic Disease Network (InFLiMeN), a virtual node to prevent and cure non-alcoholic fatty liver disease (NAFLD) at the Institute of Liver and Biliary Sciences in New Delhi.
• May 2024: Wockhardt Hospitals, in collaboration with the South Asian Liver Institute, launched an early recovery program (ERP) for liver transplantation in Mumbai. The program aims to reduce the financial burden of liver transplants by approximately 20-30 percent.
• February 2024: India's Zydus Lifesciences announced its aim to launch its first new drug in the United States by early 2026, looking to tap into the multi-billion-dollar market for treating a type of liver disease.

Liver Disease Treatment Market Report Scope:

Key Benefits for Stakeholders:

• IMARC's industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the liver disease treatment market from 2018-2032.
• The research report provides the latest information on the market drivers, challenges, and opportunities in the global liver disease treatment market.
• The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
• Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the liver disease treatment industry and its attractiveness.
• The competitive landscape allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.